Co-careldopa Tablets
Action and use
Dopa decarboxylase inhibitor + dopamine precursor; treatment of Parkinson’s disease.
Definition
Co-careldopa Tablets contain Carbidopa and Levodopa.
Content of anhydrous carbidopa, C10H14N2O4
90.0 to 110.0% of the stated amount.
Content of levodopa, C9H11NO4
95.0 to 105.0% of the stated amount.
Identification
Tests
Dissolution
Comply with the requirements for Monographs of the British Pharmacopoeia in the dissolution test for tablets and capsules, Appendix XII B1.
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
0.1m potassium dihydrogen orthophosphate adjusted to pH 3.0 with 1m orthophosphoric acid.
Calculate the total content of C10H14N2O4 and of C9H11NO4, in the medium using the declared contents of C10H14N2O4 in carbidopa BPCRS and of C9H11NO4 in levodopa BPCRS.
Assay
Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
The chromatographic conditions described under Dissolution may be used.
Calculate the content of C10H14N2O4 and of C9H11NO4 in the tablets using the declared contents of C10H14N2O4 in carbidopa BPCRS and of C9H11NO4 in levodopa BPCRS.
Labelling
The quantity of Carbidopa is stated in terms of the equivalent amount of anhydrous carbidopa.